Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Medsenic.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Medsenic
France Flag
Country
Country
France
Address
Address
11, Rue de l'académie, Strasbourg, Grand Est 67000
Telephone
Telephone
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.


Lead Product(s): Arsenic Trioxide

Therapeutic Area: Immunology Product Name: OATO

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Phebra

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 29, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The acquisition of Medsenic and its specialized pipeline in the development of optimized formulations of arsenic trioxide (Arscimed) and their applications in serious inflammatory/autoimmune conditions and other potential new indications.


Lead Product(s): Arsenic Trioxide

Therapeutic Area: Immunology Product Name: Arscimed

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Bone Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition October 25, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Bone Therapeutics would also issue and automatically allot one subscription right to each outstanding share of Bone Therapeutics, in case of statistically positive interim results of the ALLOB Phase IIb trial.


Lead Product(s): Allogeneic Bone Cell Therapy

Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ALLOB

Highest Development Status: Phase IIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Bone Therapeutics

Deal Size: $5.0 million Upfront Cash: $5.0 million

Deal Type: Acquisition August 10, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

First-line combination of Arscimed (arsenic trioxide) and prednisone in cGvHD showed an Overall Response Rate (ORR) at 6 months of 75%, allowing rapid corticosteroid tapering.


Lead Product(s): Arsenic Trioxide

Therapeutic Area: Immunology Product Name: Arscimed

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 18, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The primary endpoint of this prospective, multicenter, non-randomized study was the improvement of treatment response with Arscimed® (arsenic trioxide) in combination with prednisone, with or without cyclosporine.


Lead Product(s): Arsenic Trioxide,Prednisone,Cyclosporine

Therapeutic Area: Immunology Product Name: Arscimed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 20, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Arsenic trioxide has the unique property of increasing cellular oxidative stress to the point where it induces cell death of activated cells (enhanced apoptosis). It also has an effect on pro-inflammatory cytokines.


Lead Product(s): Arsenic Trioxide

Therapeutic Area: Immunology Product Name: Arscimed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 29, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases. Initially the oral formulation of arsenic trioxide will target the treatment of patients with chronic graft-versus-host disease.


Lead Product(s): Arsenic Trioxide

Therapeutic Area: Immunology Product Name: Arscimed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Phebra

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership June 30, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY